查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945816

基因組醫學市場－全球產業規模、佔有率、趨勢、機會及預測（按應用、最終用戶、地區和競爭格局分類，2021-2031年）

Genomic Medicine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因組醫學市場預計將從 2025 年的 396.1 億美元成長到 2031 年的 702.1 億美元，複合年成長率達到 10.01%。

基因組醫學利用個體的基因組資訊來指導臨床決策，並透過精準診斷和個人化治療策略實現客製化醫療保健。基因數據可及性的提高是推動這一市場成長的根本因素，這主要得益於DNA定序成本的大幅下降，以及需要標靶治療的慢性病和癌症在全球日益普遍。此外，各國政府對大規模人群基因組研究舉措的巨額投資也成為推動該產業發展的關鍵催化劑。正如個人化醫療聯盟所指出的，美國食品藥物管理局（FDA）預計將在2024年核准18種新型個人化藥物，凸顯了該領域對治療研發和患者照護日益成長的影響力。

市場概覽
預測期 2027-2031
市場規模：2025年 396.1億美元
市場規模：2031年 702.1億美元
複合年成長率：2026-2031年 10.01%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

然而，基因組檢測及相關服務的報銷體系往往複雜且不一致，因此市場面臨許多挑戰。進行全面基因組檢測的高昂成本以及支付方覆蓋範圍的不確定性，構成了巨大的財務障礙，阻礙了醫療機構的採用，並限制了患者的就醫途徑。這給支付方在製定清晰的效用模型方面帶來了挑戰，可能導致商業化進程延誤，並阻礙基因組醫學解決方案在常規醫療實踐中的廣泛應用。

市場促進因素

人工智慧 (AI) 與生物資訊學在基因組數據分析中的融合，正透過高效解讀龐大而複雜的生物資料集，迅速改變這一領域。隨著基因組數據的生成量超出人類的分析能力，機器學習演算法對於識別疾病生物標記和加速治療方法研發至關重要。這種技術融合正吸引大量投資。例如，成立於 2024 年 4 月的 Xaira Therapeutics 已投入超過 10 億美元，用於建立一個旨在革新藥物發現和個人化醫療的 AI 驅動平台。這筆巨額資金籌措的流入凸顯了業界向以 AI 為中心的基因組解決方案的轉變，這些解決方案能夠預測患者反應並最佳化臨床試驗，從而縮短研發週期並提高醫療干預的準確性。

同時，政府的大力資助和大規模人群基因組學計劃為檢驗不同人群的基因組學發現奠定了必要的基礎。國家生物銀行計畫正在擴大規模，以確保基因資料庫能夠反映全球多樣性，而這對於精準醫療的普遍應用至關重要。英國就是這種規模的典型例證。 2024年10月，英國研究與創新署（UKRI）報告稱，其「我們的未來健康」（Our Future Health）計畫——全球規模最大的健康研究縱向隊列研究——已達到歷史性的里程碑，招募了超過一百萬名志工。營運成本的快速下降進一步推動了這一規模的擴大。例如，Ultima Genomics公司於2024年2月商業性的UG 100定序平台，能夠以突破性的100美元價格完成人類基因基因測序。

市場挑戰

複雜且時常不一致的醫保報銷環境對全球基因組醫學市場的成長構成重大障礙。保險公司和公共醫療機構往往缺乏統一的框架來評估先進基因組檢測的臨床和效用，導致健保報銷決定難以預測，拒賠現像也屢見不鮮。這種不穩定性為醫療服務提供者帶來巨大的財務風險，如果無法保證獲得報銷，他們便會猶豫是否實施全面的檢測通訊協定。因此，經濟負擔往往轉嫁到患者身上，限制了患者獲得個人化治療的機會，並阻礙了基因組醫學從小眾應用領域向標準臨床實踐的轉變。

這種碎片化的保險覆蓋環境直接阻礙了市場擴張，造成了地理上的可及性差異。根據美國癌症協會癌症行動網路統計，截至2024年，美國僅有16個州立法強制要求州監管的保險計劃涵蓋全面的生物標記檢測。這項數據凸顯了目前基因組分析的可近性取決於患者居住而非醫療必要性，也暴露出缺乏統一的報銷機制。這種監管體系的碎片化使得診斷開發商的商業化策略複雜化，限制了檢測的普及，減緩了基因組醫學領域的收入成長。

市場趨勢

CRISPR 和新一代基因編輯療法的臨床應用正推動市場從症狀治療轉向根治性治療。這一趨勢包括編輯技術的進步、監管核准和商業性可行性檢驗，同時研發人員也在不斷改進遞送機制，以擴大目標患者群體，使其不再局限於罕見疾病。其財務影響顯而易見：CRISPR Therapeutics 於 2024 年 2 月發布的 2023 年第四季及全年財務報告累計，其首個已通過核准的CRISPR 療法的里程碑付款帶來了 8,930 萬美元的淨收入。這項盈利表明，基因編輯正在發展成為一種永續的收入來源。

液態生物檢體作為一種非侵入性癌症檢測方法，其廣泛應用正在重新定義診斷標準，透過血液檢測即可實現疾病的早期發現。此方法最大限度地降低了組織切片檢查相關的操作風險，同時能夠即時監測腫瘤進展。不斷累積的臨床療效數據促使市場對這些檢測方法在治療選擇中的應用日益廣泛。這種應用也體現在財務業績上，Guardant Health在2024年8月發布的「2024會計年度第二季財務業績」中報告稱，其營收為1.772億美元，同比成長29%。這種成長也印證了循環腫瘤DNA分析在常規腫瘤學中日益重要的作用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因組醫學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用領域（腫瘤學、心臟病學、內分泌學、罕見遺傳疾病等）
    • 依最終使用者（醫院/診所、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因組醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因組醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因組醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲基因組醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲基因組醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因組醫學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7805

The Global Genomic Medicine Market is projected to expand from USD 39.61 Billion in 2025 to USD 70.21 Billion by 2031, achieving a CAGR of 10.01%. Genomic medicine involves leveraging an individual's genomic information to guide clinical decision-making, allowing for the customization of healthcare through precise diagnosis and tailored therapeutic strategies. This market growth is fundamentally supported by the drastic reduction in DNA sequencing costs, which has enhanced the accessibility of genetic data, alongside the increasing global prevalence of chronic diseases and cancers requiring targeted interventions. Additionally, significant government investment in population-scale genomics initiatives acts as a critical catalyst for industry progress. As noted by the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 18 new personalized medicines in 2024, highlighting the sector's expanding influence on therapeutic development and patient care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 39.61 Billion
Market Size 2031USD 70.21 Billion
CAGR 2026-203110.01%
Fastest Growing SegmentOncology
Largest MarketNorth America

However, the market faces a major obstacle due to the complex and often inconsistent reimbursement landscape for genomic testing and related services. The high costs involved in implementing comprehensive genomic assays, combined with uncertain coverage policies from payers, create substantial financial barriers that deter provider adoption and limit patient access. This difficulty in defining clear economic utility models for insurers risks slowing the commercialization process and hindering the broader integration of genomic medicine solutions into routine medical practice.

Market Driver

The integration of Artificial Intelligence and Bioinformatics for genomic data analysis is rapidly transforming the sector by enabling the efficient interpretation of massive and complex biological datasets. With genomic data generation exceeding human analytical capabilities, machine learning algorithms have become essential for identifying disease biomarkers and accelerating therapeutic development. This technological convergence is attracting significant investment; for example, Xaira Therapeutics launched in April 2024 with over $1 billion in committed capital to build an AI-driven platform aimed at revolutionizing drug discovery and personalized medicine. Such substantial capital inflows underscore the industry's shift toward AI-centric genomic solutions that can predict patient responses and optimize clinical trials, thereby shortening development timelines and improving the precision of medical interventions.

Simultaneously, robust government funding and large-scale population genomics initiatives are providing the necessary infrastructure to validate these genomic insights across diverse groups. National biobanking projects are scaling up to ensure genetic databases reflect global diversity, which is critical for the universal applicability of precision medicine. A prime example of this scale is in the UK, where UK Research and Innovation reported in October 2024 that the Our Future Health programme reached a historic milestone by recruiting over 1 million volunteers, establishing itself as the world's largest longitudinal cohort study for health research. This expansion is further facilitated by plummeting operational costs, demonstrated when Ultima Genomics commercially launched its UG 100 sequencing platform in February 2024, enabling full human genome sequencing for a breakthrough price of just $100.

Market Challenge

The complex and frequently inconsistent reimbursement landscape constitutes a formidable barrier to the growth of the Global Genomic Medicine Market. Insurers and public payers often lack unified frameworks for evaluating the clinical and economic utility of advanced genomic assays, leading to unpredictable coverage decisions and frequent claim denials. This volatility creates significant financial risks for healthcare providers, who are hesitant to adopt comprehensive testing protocols if payment is not guaranteed. Consequently, the economic burden often shifts to patients, restricting access to personalized therapies and stifling the transition of genomic medicine from niche applications to standard clinical practice.

This fragmented coverage environment directly hampers market expansion by creating geographic disparities in accessibility. According to the American Cancer Society Cancer Action Network, in 2024, legislation requiring state-regulated insurance plans to cover comprehensive biomarker testing had been enacted in only 16 U.S. states. This statistic underscores the lack of a cohesive reimbursement strategy, as access to essential genomic profiling largely depends on a patient's location rather than medical necessity. Such regulatory patchworks complicate commercialization strategies for diagnostic developers and limit test volumes, thereby slowing the overall revenue growth of the genomic medicine sector.

Market Trends

The clinical translation of CRISPR and next-generation gene editing therapies is shifting the market from symptomatic management to curative interventions. This trend involves the progression of editing technologies to regulatory approvals, validating their commercial viability, while developers refine delivery mechanisms to broaden the addressable patient population beyond rare diseases. The financial impact is evident; according to CRISPR Therapeutics' 'Fourth Quarter and Full Year 2023 Financial Results' released in February 2024, the company reported a net income of $89.3 million, driven by milestone payments for the first approved CRISPR-based therapy. This profitability signals that gene editing is evolving into a sustainable revenue generator.

The proliferation of liquid biopsy for non-invasive cancer detection is redefining diagnostic standards by enabling early disease interception via blood-based testing. This approach minimizes procedural risks associated with tissue biopsies while facilitating real-time monitoring of tumor evolution. The market is witnessing increased adoption of these assays for therapy selection, supported by accumulating clinical validity data. This utilization is reflected in financial performance; according to Guardant Health's 'Second Quarter 2024 Financial Results' in August 2024, the company reported revenue of $177.2 million, a 29% increase compared to the prior year. Such growth underscores the expanding role of circulating tumor DNA analysis in routine oncology.

Key Market Players

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies

Report Scope

In this report, the Global Genomic Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Medicine Market, By Application

  • Oncology
  • Cardiology
  • Endocrinology
  • Rare Genetic Disorders
  • Others

Genomic Medicine Market, By End User

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others

Genomic Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Medicine Market.

Available Customizations:

Global Genomic Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Oncology, Cardiology, Endocrinology, Rare Genetic Disorders, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Genomic Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genomic Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Genomic Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Genomic Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End User

7. Europe Genomic Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genomic Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End User
    • 7.3.2. France Genomic Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Genomic Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Genomic Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Genomic Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End User

8. Asia Pacific Genomic Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genomic Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End User
    • 8.3.2. India Genomic Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Genomic Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Genomic Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Genomic Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End User

9. Middle East & Africa Genomic Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genomic Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Genomic Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Genomic Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End User

10. South America Genomic Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genomic Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Genomic Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Genomic Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genomic Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. BGI Genomics Co., Ltd.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. QIAGEN N.V.
  • 15.6. Agilent Technologies, Inc.
  • 15.7. Invitae Corporation
  • 15.8. PerkinElmer, Inc.
  • 15.9. Pacific Biosciences of California, Inc.
  • 15.10. Oxford Nanopore Technologies

16. Strategic Recommendations

17. About Us & Disclaimer